Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
KEY HIGHLIGHTS AU$4,000,000 initial fundingEquity placement component of up to additional AU$22,000,000 in ordinary shares over 12 monthsFlexible funding package leading up to a proposed U.S....
-
KEY HIGHLIGHTS LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC) Clinical data shows combining Veyonda® with radiopharmaceutical, 177Lu-PSMA-617, is...
-
LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda® 1200 mgThe objective is to see whether the dose-response effect seen to date will lead to even greater...
-
Data published today describes positive interim results from the LuPIN trial Veyondaâ (NOX66) dose-finding study69% combined PSA response rate is higher than that observed in studies of 177Lu-PSMA-617...
-
Long-lasting responses with Veyonda® + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatmentComplete resolution of pain...
-
New class of immuno-oncology drug identifiedActivator of NK cells and CD4+ immune cellsPotential to boost function of current immuno-oncology drugs. SYDNEY, Australia, April 16, 2019 (GLOBE...
-
Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancersU.S. study to investigate Veyonda® + doxorubicin in sarcomasCEP-2 target start Q4...
-
Interim (12-week) DARRT-1 readout Combination Veyonda® + low-dose radiotherapy well toleratedPSA, pain and tumour responses at higher doses24-week readout to indicate longevity of response. SYDNEY,...
-
Lu-PIN-1 Study two-thirds enrolledStudy testing ability of Veyonda® to boost effect of Novartis experimental drugNoxopharm to initiate LuPIN-2 study. SYDNEY, Australia, Jan. 14, 2019 (GLOBE...
-
Final CEP-1 data confirm tolerability of Veyonda® alone and in combination with carboplatinHalt in progression of cancer growth in 50% of patients Study provides proof-of-concept for well-tolerated...